site logo

Ami Lifesciences named Amit Kaptain as CEO

Amit Kaptain has been named CEO by Ami Lifesciences, a company that manufactures and exports active pharmaceutical ingredients.

Amit will be accountable for creating business strategies and enduring global alliances with top pharmaceutical firms (including Big Pharma and Innovators) by producing goods in specialised therapeutic areas and establishing himself as an Indian company that can be relied upon.

Ami Lifesciences was started in 2004 by a first-generation entrepreneur, Girish Chovatia. Kedaara acquired a significant minority in Ami Lifesciences in February 2020. This is Kedaara’s first investment in the API sector, and second investment in healthcare. Company has scaled at a CAGR of 25%+ to a revenue of ~INR 550crs. In order to achieve our vision of becoming one of India’s pure-play third-party API players, Company and Kedaara have embarked upon the journey of augmenting the leadership team, and Amit’s recruitment is the first step in that direction. We will continue to onboard high quality leadership and technical talent from the industry.

With 20+ years of experience in the API industry, Amit is a seasoned professional in driving sales, marketing and operations across global markets and has worked with large Indian MNCs such as Dr. Reddy’s, Ranbaxy, and Sun Pharma. Prior to joining Ami Lifesciences, Amit worked as COO at Aurore Lifesciences. Prior to that Amit worked at Dr. Reddy’s (DRL) for 7 years in various leadership roles and managed one of the top 10 P&L’s in the API industry globally. At DRL, Amit was also responsible for product portfolio & strategy, customer service and new market development. At Ranbaxy, Amit was Head of Global API Sales & Marketing and was responsible for driving new product development. Amit spent ~6 years with Sun Pharma where he was responsible for sales & marketing in India, Far & South-East Asia. He is a B.Sc. in Chemistry and Master of Marketing Management, NMIMS from University of Mumbai.

Girish Chovatia, Chairman and Managing Director, Ami Lifesciences said, “India has emerged as a major pharmaceutical hub and witnessed increasing demand for APIs from around the globe. With our scientific and technological capabilities, research and manufacturing competencies, Ami Lifesciences is poised to maximise its impact on the global pharmaceutical industry. We are delighted to welcome Amit to the team. Amit has 20+ years of strong domain expertise in the API sector and has undertaken diverse leadership roles at Dr. Reddy’s Laboratories, SunPharma and Ranbaxy. We are confident that Ami Lifesciences will emerge as one of India’s leading and reliable API supplier under Amit’s leadership.”

Nishant Sharma, CIO & Managing Partner of Kedaara Capital said, “COVID-19 pandemic has prompted pharmaceutical companies across the globe to adopt a “China Plus One” strategy. The Indian Government is urging Indian companies to take advantage of the opportunity to become a viable and a reliable alternative to China. We are excited to welcome Amit and are confident of executing on our strategy by leveraging Amit’s entrepreneurial, leadership, commercial and operational prowess. We will continue to build out the leadership team by recruiting experienced, high-quality professionals from the industry.”

Amit Kaptain said, “I am very excited to be a part of the Ami Lifesciences growth story, and partner with Girish Chovatia and the Kedaara team. I am personally very excited about the prospects of the API industry, and will leverage Ami Lifesciences’ strong product portfolio, R&D capabilities, and manufacturing competencies to create a world class leader which will be a reliable partner of choice from India. I am looking forward to working with the experienced team of Ami Lifesciences to achieve the company’s vision, growth, and expansion plans.”

Subscribe Us